2,016
Views
0
CrossRef citations to date
0
Altmetric
Original research

Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database

, , , ORCID Icon, , , & show all
Pages 1135-1144 | Received 29 Apr 2021, Accepted 17 Jun 2021, Published online: 08 Jul 2021

References

  • Roux J, Guilleux A, Lefort M, et al. Use of healthcare services by patients with multiple sclerosis in France over 2010–2015: a nationwide population-based study using health administrative data. Mult Scler J Exp Transl Clin. 2019;5(4):205521731989609. .
  • Foulon S, Maura G, Dalichampt M, et al. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. 2017;264::1185–1192.
  • Multiple sclerosis international federation. Atlas of MS 2013 - Mapping multiple sclerosis around the world [Internet]. London, UK: Multiple sclerosis international federation; 2014. 28. Available from: http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report
  • Iacobaeus E, Arrambide G, Amato MP, et al. Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler. 2020 Jun 12;26(9):1352458520925369. DOI:https://doi.org/10.1177/1352458520925369.
  • Arrambide G, Iacobaeus E, Amato MP, et al. Aggressive multiple sclerosis (2): treatment. Mult Scler. 2020 Jun 12;26(9):1352458520924595. DOI:https://doi.org/10.1177/1352458520924595.
  • Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–224.
  • Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–279.
  • Fattore G, Lang M, Pugliatti M. The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring the socioeconomic consequences of multiple sclerosis. Mult Scler. 2012;18:5–6.
  • Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19:e11–25.
  • Lebrun-Frenay C, Kobelt G, Berg J, et al. European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for France. Mult Scler. 2017;23:65–77.
  • Raimundo K, Tian H, Zhou H, et al. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res. 2013;13:131.
  • Lefeuvre D, Rudant J, Foulon S, et al. Healthcare expenditure of multiple sclerosis patients in 2013: a nationwide study based on French health administrative databases. Mult Scler J Exp Transl Clin [Internet]. 2017 3, [cited 2017 Oct 6]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600306/
  • Kobelt G, Thompson A, Berg J, Group the MS, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J [Internet]. SAGE PublicationsSage UK: London, England; 2017 [cited 2020 Sep 11]; Available from: https://journals.sagepub.com/doi/10.1177/1352458517694432?icid=int.sj-related-articles.similar-articles.16
  • Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d’Épidémiologie et de Santé Publique. 2017;65:S149–67.
  • Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954–962.
  • Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78:161–175.
  • Centre des liaisons européennes et internationales de sécurité sociale, République Française. The French Social Security System. I-Health, maternity, paternity, disability, and death [Internet]. Vous informer sur la protection sociale à l’international. 2020 [cited 2020 Oct 12]. Available from: https://www.cleiss.fr/docs/regimes/regime_france/an_1.html
  • Heinzlef O, Molinier G, van Hille B, et al. Economic burden of the out-of-pocket expenses for people with multiple sclerosis in France. Pharmaco Economics Open [Internet]. 2020 cited 2020 Sep 24. DOI:https://doi.org/10.1007/s41669-020-00199-7.
  • Chevreul K, Berg Brigham K, Durand-Zaleski I, et al. France: health system review. Health Syst Transit. 2015;17:1–218,xvii.
  • Arrêt maladie [Internet]. [cited 2020 Sep 15]. Available from: https://www.ameli.fr/assure/remboursements/indemnites-journalieres/arret-maladie
  • Pensions d’invalidité [Internet]. [cited 2020 Sep 15]. Available from: https://www.ameli.fr/entreprise/vos-salaries/montants-reference/pension-invalidite
  • Detournay B, Debouverie M, Pereira O, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36:101396.
  • Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120, SAGE Publications Ltd STM
  • Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PLOS ONE. 2019 Sep 19;14(9):e0222012. DOI:https://doi.org/10.1371/journal.pone.0222012.
  • Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18:7–15.
  • Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–647.
  • Chevalier J, Chamoux C, Hammès F, et al. Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective. Ramagopalan SV, editor. PLoS ONE. 2016;11:e0150703.
  • Petruzzo M, Palladino R, Nardone A, et al. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;38:101514.
  • Bosco-Lévy P, Debouverie M, Brochet B, et al. Validation d’un algorithme complexe d’identification de poussées dans la sclérose en plaque (SEP) à partir du Système National des Données de Santé (SNDS). Revue Neurologique [Internet], s81–2, Elsevier; 2020;176 (Suppl):S81-S82. [cited 2020 Sep 23]. Available from: https://www.em-consulte.com/article/1387114/alertePM
  • Vermersch P, Suchet L, Colamarino R, et al. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult Scler Relat Disord. 2020;46:102521.
  • Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162.
  • World Health Organization, editor. The world health report 2000: health systems: improving performance. Geneva: WHO; 2000.